<!DOCTYPE html>
<!--[if IE 8]><html class="no-js lt-ie9" lang="en" > <![endif]-->
<!--[if gt IE 8]><!--> <html class="no-js" lang="en" > <!--<![endif]-->
<head>
  <meta charset="utf-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  
  <meta name="author" content="David Leon (Dawei Leng)">
  <link rel="shortcut icon" href="../img/favicon.ico">
  <title>Data Mining - Targeting 2019-nCoV Portal</title>
  <link href='https://fonts.googleapis.com/css?family=Lato:400,700|Roboto+Slab:400,700|Inconsolata:400,700' rel='stylesheet' type='text/css'>

  <link rel="stylesheet" href="../css/theme.css" type="text/css" />
  <link rel="stylesheet" href="../css/theme_extra.css" type="text/css" />
  <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
  
  <script>
    // Current page data
    var mkdocs_page_name = "Data Mining";
    var mkdocs_page_input_path = "CoV_Experiment_Data.md";
    var mkdocs_page_url = null;
  </script>
  
  <script src="../js/jquery-2.1.1.min.js" defer></script>
  <script src="../js/modernizr-2.8.3.min.js" defer></script>
  <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js"></script>
  <script>hljs.initHighlightingOnLoad();</script> 
  
</head>

<body class="wy-body-for-nav" role="document">

  <div class="wy-grid-for-nav">

    
    <nav data-toggle="wy-nav-shift" class="wy-nav-side stickynav">
      <div class="wy-side-nav-search">
        <a href=".." class="icon icon-home"> Targeting 2019-nCoV Portal</a>
        <div role="search">
  <form id ="rtd-search-form" class="wy-form" action="../search.html" method="get">
    <input type="text" name="q" placeholder="Search docs" title="Type search term here" />
  </form>
</div>
      </div>

      <div class="wy-menu wy-menu-vertical" data-spy="affix" role="navigation" aria-label="main navigation">
	<ul class="current">
	  
          
            <li class="toctree-l1">
		
    <a class="" href="..">Home</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../drug_candidates/">2019-nCoV Community Effort</a>
	    </li>
          
            <li class="toctree-l1">
		
    <span class="caption-text">Data Download</span>
    <ul class="subnav">
                <li class=" current">
                    
    <a class="current" href="./">Data Mining</a>
    <ul class="subnav">
            
    <li class="toctree-l3"><a href="#initial-data-analysis-results">Initial Data Analysis Results</a></li>
    
        <ul>
        
            <li><a class="toctree-l4" href="#1-top-target-rdrp-specific-antiviral-candidates">1. Top target (RdRp) specific antiviral candidates</a></li>
        
            <li><a class="toctree-l4" href="#2-top-antiviral-candidates-selected-from-viral-replication-assay">2. Top antiviral candidates selected from viral replication assay</a></li>
        
            <li><a class="toctree-l4" href="#3-top-antiviral-candidates-selected-from-different-assays">3. Top antiviral candidates selected from different assays</a></li>
        
            <li><a class="toctree-l4" href="#1-pharmacologic-substance">1. Pharmacologic Substance</a></li>
        
            <li><a class="toctree-l4" href="#2-organic-chemicals">2. Organic chemicals</a></li>
        
            <li><a class="toctree-l4" href="#3-amino-acidspeptidesproteins">3. Amino acids/peptides/proteins</a></li>
        
        </ul>
    

    <li class="toctree-l3"><a href="#data-download-with-explanation-and-preview">Data Download with Explanation and Preview</a></li>
    
        <ul>
        
            <li><a class="toctree-l4" href="#compound-libraries-for-drug-repurposing">Compound Libraries for drug repurposing.</a></li>
        
            <li><a class="toctree-l4" href="#previous-drug-discovery-effort-for-sarsmers">Previous drug discovery effort for SARS/MERS</a></li>
        
        </ul>
    

    </ul>
                </li>
                <li class="">
                    
    <a class="" href="../nCov_Targets/">Target Validation</a>
                </li>
                <li class="">
                    
    <a class="" href="../nCov_Structures/">Structure Modeling</a>
                </li>
                <li class="">
                    
    <a class="" href="../research_progress/">Research Articles</a>
                </li>
    </ul>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../contact_us/">Community Discussion</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../useful_links/">Useful Links</a>
	    </li>
          
            <li class="toctree-l1">
		
    <a class="" href="../history/">History</a>
	    </li>
          
        </ul>
      </div>
      &nbsp;
    </nav>

    <section data-toggle="wy-nav-shift" class="wy-nav-content-wrap">

      
      <nav class="wy-nav-top" role="navigation" aria-label="top navigation">
        <i data-toggle="wy-nav-top" class="fa fa-bars"></i>
        <a href="..">Targeting 2019-nCoV Portal</a>
      </nav>

      
      <div class="wy-nav-content">
        <div class="rst-content">
          <div role="navigation" aria-label="breadcrumbs navigation">
  <ul class="wy-breadcrumbs">
    <li><a href="..">Docs</a> &raquo;</li>
    
      
        
          <li>Data Download &raquo;</li>
        
      
    
    <li>Data Mining</li>
    <li class="wy-breadcrumbs-aside">
      
    </li>
  </ul>
  <hr/>
</div>
          <div role="main">
            <div class="section">
              
                <h1 id="initial-data-analysis-results">Initial Data Analysis Results</h1>
<p><details>
      <summary>I. Based on previous experimental data </summary></p>
<h3 id="1-top-target-rdrp-specific-antiviral-candidates">1. Top target (RdRp) specific antiviral candidates</h3>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>DrugBank ID</th>
<th>Clinical Information</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Method</th>
<th>parameter</th>
<th>PX</th>
<th>mean</th>
<th>unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>1. Phase III for  Ebola <br>2. Phase III for nCoV</td>
<td>RNA-Directed RNA Polymerase Inhibitor</td>
<td>Ebola virus disease remission/reduction, IN VITRO</td>
<td></td>
<td>IC-50</td>
<td>8</td>
<td>0.00000001</td>
<td>M</td>
</tr>
<tr>
<td>Lumicitabine</td>
<td><a href="https://www.drugbank.ca/drugs/DB14808">DB14808</a></td>
<td>Phase II  completed for Respiratory Syncytial Virus</td>
<td>RNA-Directed RNA Polymerase (Respiratory Syncytial Virus) Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>6.58</td>
<td>0.00000026</td>
<td>M</td>
</tr>
<tr>
<td>Sofosbuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB08934">DB08934</a></td>
<td>Phase 4 completed  for HCV <br>Marketed for HCV</td>
<td>RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, dengue virus remission/reduction, IN VITRO</td>
<td>Plaque assay</td>
<td>IC-90</td>
<td>6.40</td>
<td>0.0000004</td>
<td>M</td>
</tr>
<tr>
<td>Adafosbuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14906">DB14906</a></td>
<td>Phase II  completed for HCV</td>
<td>RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, dengue virus remission/reduction, IN VITRO</td>
<td>Plaque assay</td>
<td>IC-50</td>
<td>5.96</td>
<td>0.0000011</td>
<td>M</td>
</tr>
<tr>
<td>Balapiravir hydrochloride</td>
<td><a href="https://www.drugbank.ca/drugs/DB12283">DB12283</a></td>
<td>1. Phase I  completed for Dengue Fever <br>2. Phase II completed for HCV</td>
<td>RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, dengue virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>5.72</td>
<td>0.0000019</td>
<td>M</td>
</tr>
<tr>
<td>Galidesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB11676">DB11676</a></td>
<td>1. Phase I competed  for Ebola <br>2. Phase I started for Marburg virus <br>3. Phase 1 started for yellow fever</td>
<td>RNA Polymerase Inhibitors</td>
<td>Infection, Zika virus remission/reduction, IN VITRO</td>
<td>Fluorescent assay</td>
<td>IC-50</td>
<td>5.53</td>
<td>0.00000296</td>
<td>M</td>
</tr>
<tr>
<td>Beclabuvir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12225">DB12225</a></td>
<td>Phase III  completed for HCV, Phase IV withdrawn for HCV</td>
<td>RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, herpes simplex virus remission/reduction, IN VITRO</td>
<td>Viral replication assay (multiple cycle)</td>
<td>IC-50</td>
<td>5.40</td>
<td>0.000004</td>
<td>M</td>
</tr>
<tr>
<td>Favipiravir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12466">DB12466</a></td>
<td>1. Phase III  completed for Influenza <br>2. Phase II completed for Ebola</td>
<td>RNA-Directed RNA Polymerase (Influenza A Virus H1N1) Inhibitors;RNA-Directed RNA Polymerase (NS5B) (HCV) Inhibitors</td>
<td>Infection, rabies virus remission/reduction, IN VITRO</td>
<td>Fluorescent assay</td>
<td>MIC</td>
<td>5.40</td>
<td>0.000004</td>
<td>M</td>
</tr>
</tbody>
</table>
<h3 id="2-top-antiviral-candidates-selected-from-viral-replication-assay">2. Top antiviral candidates selected from viral replication assay</h3>
<table>
<thead>
<tr>
<th>Drug name</th>
<th>DrugBank ID</th>
<th>Clinical Information</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Method</th>
<th>parameter</th>
<th>PX</th>
<th>mean</th>
<th>unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferiprone</td>
<td><a href="https://www.drugbank.ca/drugs/DB08826">DB08826</a></td>
<td>1. Phase 4 completed  for acute iron intoxication <br/>2. Phase 4 completed for Hepatic impairment <br/>3.  Phase 4 completed for impaired kidney function <br/>4. Phase 4 completed for  Beta-Thalassemia <br/>5. Phase 4 completed for hemosiderosis <br/>6. Phase 4  completed for Prolonged QT Interval <br/>7. Phase III completed for Parkinson's  disease; <br/>Marketed for iron toxicity</td>
<td>Chelating Agents;Cytochrome P450 CYP4F2 Inhibitors</td>
<td>Infection, BK polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>8.46</td>
<td>3.50E-09</td>
<td>M</td>
</tr>
<tr>
<td>Raltegravir potassium</td>
<td><a href="https://www.drugbank.ca/drugs/DB06817">DB06817</a></td>
<td>Phase 4 completed  for HIV <br/>Marketed for Anti-Retroviral HIV</td>
<td>HIV Integrase Inhibitors</td>
<td>Infection, xenotropic murine leukemia virus-related virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>8.30</td>
<td>0.000000005</td>
<td>M</td>
</tr>
<tr>
<td>Verdinexor</td>
<td><a href="https://www.drugbank.ca/drugs/DB12207">DB12207</a></td>
<td>Phase 1 completed  for basic science on health volunteers</td>
<td>Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators</td>
<td>Infection, JC polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>8.12</td>
<td>7.50E-09</td>
<td>M</td>
</tr>
<tr>
<td>Brincidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12151">DB12151</a></td>
<td>Phase 3 completed  for adenovirus infections</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, JC polyomavirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7.7</td>
<td>0.00000002</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB14761">DB14761</a></td>
<td>1. Phase III for  Ebola <br> 2. Phase III for nCoV</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Middle East respiratory syndrome coronavirus (MERS-CoV) remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7.60</td>
<td>0.000000025</td>
<td>M</td>
</tr>
<tr>
<td>Verdinexor</td>
<td><a href="https://www.drugbank.ca/drugs/DB12207">DB12207</a></td>
<td>Phase I completed  for basic science experiments on healthy volunteers</td>
<td>Exportin-1 (CRM1, XPO1) Receptor Antagonists;Signal Transduction Modulators</td>
<td>Infection, adenovirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7.52</td>
<td>0.00000003</td>
<td>M</td>
</tr>
<tr>
<td>Cidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB00369">DB00369</a></td>
<td>Phase 4 completed  for cytomegalovirus <br/>Marketed for CMV in AIDS patients</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-99</td>
<td>7.22</td>
<td>0.00000006</td>
<td>M</td>
</tr>
<tr>
<td>Alvocidib hydrochloride</td>
<td><a href="https://www.drugbank.ca/drugs/DB03496">DB03496</a></td>
<td>1. Phase II  completed for sarcomas <br>2. Phase II completed for renal cancers; <br>3. Phase II  completed for melanoma <br>4. Phase II completed for other cancers including:  myeloma, carcinoma, esophageal, endometrial, leukaemia, etc.</td>
<td>Cyclin-Dependent Kinase 1 (CDK1) Inhibitors;Signal Transduction Modulators;Cyclin-Dependent Kinase 6 (CDK6) Inhibitors;CDK9/Cyclin T1 Inhibitors;Baculoviral IAP Repeat-Containing Protein 5 (BIRC5; Survivin) Inhibitors;Apoptosis Inducers;Cyclin-Dependent Kinase 7 (CDK7) Inhibitors;Cyclin-Dependent Kinase 2 (CDK2) Inhibitors;Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Inhibitors;Cyclin-Dependent Kinase 4 (CDK4) Inhibitors;X-Chromosome-Linked Inhibitor of Apoptosis Protein (XIAP) Inhibitors;Apoptosis Regulator Bcl-2 Inhibitors</td>
<td>Infection, herpes virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7.00</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Ganciclovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB01004">DB01004</a></td>
<td>1. Phase 4 active  for viral pneumonia <br>2. Phase 4 completed for DNA virus infections <br>3. Phase 4  completed for CMV <br>4. Phase 4 completed for viral sepsis</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, herpes simplex virus remission/reduction, IN VITRO</td>
<td>Viral replication assay</td>
<td>IC-50</td>
<td>7</td>
<td>0.0000001</td>
<td>M</td>
</tr>
</tbody>
</table>
<h3 id="3-top-antiviral-candidates-selected-from-different-assays">3. Top antiviral candidates selected from different assays</h3>
<table>
<thead>
<tr>
<th>Drug_name</th>
<th>DrugBank  ID</th>
<th>Clinical Information</th>
<th>Mechanism of action</th>
<th>Experimental activity</th>
<th>Method</th>
<th>parameter</th>
<th>PX</th>
<th>mean</th>
<th>unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presatovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12165">DB12165</a></td>
<td>Phase II completed  for Respiratory Syncytial Virus</td>
<td>Respiratory Syncytial Virus (RSV) Fusion Inhibitors;Viral Fusion Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>Cytopathicity assay</td>
<td>IC-50</td>
<td>11.74</td>
<td>1.80E-12</td>
<td>M</td>
</tr>
<tr>
<td>Brincidofovir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12151">DB12151</a></td>
<td>Phase III completed  for AdV, BKV, CMV, EBV, and HHV6</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>DNA assay</td>
<td>IC-50</td>
<td>11.70</td>
<td>2.00E-12</td>
<td>M</td>
</tr>
<tr>
<td>Sorivudine</td>
<td><a href="https://www.drugbank.ca/drugs/DB11998">DB11998</a></td>
<td>Phase III  completed for Chickenpox, HIV</td>
<td>DNA Polymerase Inhibitors</td>
<td>Infection, varicella zoster virus remission/reduction, IN VITRO</td>
<td>Plaque assay</td>
<td>IC-50</td>
<td>10.62</td>
<td>2.40E-11</td>
<td>M</td>
</tr>
<tr>
<td>Peramivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB06614">DB06614</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate</td>
<td>Ki</td>
<td>10.85</td>
<td>1.40E-11</td>
<td>M</td>
</tr>
<tr>
<td>Peramivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB06614">DB06614</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>4-Methylumbelliferyl-N-acetyl-alpha-D-neuraminic acid as substrate</td>
<td>IC-50</td>
<td>10.30</td>
<td>5.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Zanamivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB00558">DB00558</a></td>
<td>Phase 4 completed  for influenza <br/>Marketed for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>Chemiluminescent assay</td>
<td>IC-50</td>
<td>10.52</td>
<td>3.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Sirolimus</td>
<td><a href="https://www.drugbank.ca/drugs/DB00877">DB00877</a></td>
<td>1. Phase 4 completed  for renal diseases, renal failure <br>2. Phase 4 completed for kidney and heart  transplatation <br/>Marketed for kidney transplantation</td>
<td>CCR5 Expression Inhibitors;Cytochrome P450 CYP2D6 Inhibitors;Signal Transduction Modulators;Cytochrome P450 CYP2C9 Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;Proteasome Inhibitors;Mammalian Target of Rapamycin (mTOR; FRAP1) Inhibitors;Drugs Targeting B-Lymphocyte Antigen CD19</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>Chemiluminescent assay</td>
<td>IC-50</td>
<td>10.40</td>
<td>4.00E-11</td>
<td>M</td>
</tr>
<tr>
<td>Laninamivir</td>
<td><a href="https://www.drugbank.ca/drugs/DB12791">DB12791</a></td>
<td>Phase I completed  for influenza</td>
<td>Neuraminidase (Sialidase) (Influenza Virus) Inhibitors</td>
<td>Neuraminidase (nonspecified subtype) (Influenza A virus) inhibition, IN VITRO</td>
<td>Fluorescent assay</td>
<td>IC-50</td>
<td>9.96</td>
<td>1.10E-10</td>
<td>M</td>
</tr>
<tr>
<td>Ribavirin</td>
<td><a href="https://www.drugbank.ca/drugs/DB00811">DB00811</a></td>
<td>1. nCoV clinical  trial <br>2. Phase 4 completed for HCV <br>3. Phase 3 completed for HBV <br/>Marketed for RSV, HCV,</td>
<td>Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors</td>
<td>Infection, respiratory syncytial virus (RSV) remission/reduction, IN VITRO</td>
<td>ELISA assay</td>
<td>IC-50</td>
<td>9.90</td>
<td>1.26E-10</td>
<td>M</td>
</tr>
</tbody>
</table>
</details>

<p><br></p>
<p><details>
      <summary>II. Based on sematic literature mining </summary></p>
<h3 id="1-pharmacologic-substance">1. Pharmacologic Substance</h3>
<table>
<thead>
<tr>
<th>Source Concept</th>
<th>Source Concept Categories</th>
<th>Relationship Type</th>
<th>Target Concept</th>
<th>Target Concept Categories</th>
<th>Score</th>
<th>Count of Evidence</th>
<th>Evidence contains clinical studies?</th>
<th>Count of Evidence per rel type</th>
</tr>
</thead>
<tbody>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>7.9481972</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>proteasome inhibitor</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>6.504773223</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>hiv protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>2.051117514</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cardiotonic agents</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>Virus</td>
<td>1.367411676</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>chinese herbs</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>1.367411676</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>anthelmintics</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>1.367411676</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>antiviral agents</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>Virus</td>
<td>1.093929341</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>kinase inhibitor</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>1.093929341</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
</tbody>
</table>
<h3 id="2-organic-chemicals">2. Organic chemicals</h3>
<table>
<thead>
<tr>
<th>Source Concept</th>
<th>Source Concept Categories</th>
<th>Relationship Type</th>
<th>Target Concept</th>
<th>Target Concept Categories</th>
<th>Score</th>
<th>Count of Evidence</th>
<th>Evidence contains clinical studies?</th>
<th>Count of Evidence per rel type</th>
</tr>
</thead>
<tbody>
<tr>
<td>fk-506</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus nl63</td>
<td>Virus</td>
<td>10.64417436</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>glycyrrhizic acid</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>8.142055669</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>Virus</td>
<td>7.560480264</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 2, UNIDIRECTIONAL: 1</td>
</tr>
<tr>
<td>beta-thujaplicin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>Virus</td>
<td>7.096116243</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>lopinavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>5.913430203</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>u 18666a</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>coronavirus, feline</td>
<td>Virus</td>
<td>5.322087182</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>5-(n,n-hexamethylene)amiloride</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>Virus</td>
<td>5.322087182</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>niclosamide</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>5.322087182</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>fumaric acid</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>Virus</td>
<td>4.730744162</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>tapi-2</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>4.730744162</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
</tbody>
</table>
<h3 id="3-amino-acidspeptidesproteins">3. Amino acids/peptides/proteins</h3>
<table>
<thead>
<tr>
<th>Source Concept</th>
<th>Source Concept Categories</th>
<th>Relationship Type</th>
<th>Target Concept</th>
<th>Target Concept Categories</th>
<th>Score</th>
<th>Count of Evidence</th>
<th>Evidence contains clinical studies?</th>
<th>Count of Evidence per rel type</th>
</tr>
</thead>
<tbody>
<tr>
<td>human leukocyte interferon</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>11.88168037</td>
<td>17</td>
<td>no</td>
<td>DOWNREGULATE: 11, UNIDIRECTIONAL: 4, UPREGULATE: 1, NEG_UNIDIRECTIONAL: 1</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>9.45060033</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>recombinant interferon alfa</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>9.067622441</td>
<td>5</td>
<td>no</td>
<td>DOWNREGULATE: 4, UNIDIRECTIONAL: 1</td>
</tr>
<tr>
<td>cytokine</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>5.9611479</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 2, UNIDIRECTIONAL: 1</td>
</tr>
<tr>
<td>glycosyltransferase</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>5.913430203</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>methyltransferase</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>Virus</td>
<td>5.913430203</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>monoclonal antibodies</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>porcine respiratory coronavirus</td>
<td>Virus</td>
<td>4.730744162</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>spike protein antibody</td>
<td>Amino Acid, Peptide, or Protein</td>
<td>DOWNREGULATE</td>
<td>bovine coronavirus</td>
<td>Virus</td>
<td>4.730744162</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
</tbody>
</table>
</details>

<hr />
<h1 id="data-download-with-explanation-and-preview">Data Download with Explanation and Preview</h1>
<p>We are releasing the following datasets from our big data platform. We are making our best efforts to mine all experimental data of previous coronavirus related studies. If you have other specific data need or have datasets to contribute, please contact us @<a href="https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues"><strong>here</strong></a>. We will update our datasets periodically to provide more information to help your research combat the disease. </p>
<h2 id="compound-libraries-for-drug-repurposing">Compound Libraries for drug repurposing.</h2>
<ul>
<li>Please visit <a href="https://www.drugbank.ca/">Drugbank</a> to download the most recent data
   The latest release of DrugBank (version 5.1.5, released 2020-01-03) contains 13,490 drug entries including 2,636 approved small molecule drugs, 1,365 approved biologics (proteins, peptides, vaccines, and allergenics), 131 nutraceuticals and over 6,350 experimental (discovery-phase) drugs. Additionally, 5,191 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.</li>
</ul>
<h2 id="previous-drug-discovery-effort-for-sarsmers">Previous drug discovery effort for SARS/MERS</h2>
<ul>
<li>
<p>A collection of clinical and preclinical drug pipelines related to SARS/MERS, but without clinical conclusion. Most of these pipelines are deactivated.  </p>
</li>
<li>
<p>Downloadable datasets: </p>
<ul>
<li><a href="http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_clinicaldrug_sars.csv">Drugs in pipeline for SARS</a></li>
<li><a href="http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_clinicaldrug_mers.csv">Drugs in pipeline for MERS</a></li>
<li><a href="http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_clinicaldrug_cov.csv">Drugs in pipeline for Coronavirus</a></li>
</ul>
</li>
</ul>
<h3 id="annotated-preclinical-studies">Annotated preclinical studies</h3>
<ul>
<li>
<p>A collection of 1690 in vitro and in vivo records for 245 molecules     </p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/SARS_annotated_1690.csv">Full dataset</a></p>
</li>
</ul>
<p><details>
      <summary>A few selected records</summary></p>
<table>
<thead>
<tr>
<th>drug_name</th>
<th>tested_activity</th>
<th>MOA_summary</th>
<th>condition</th>
<th>method</th>
<th>material</th>
<th>parameter</th>
<th>operator</th>
<th>mean value</th>
<th>unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>PF-835231</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.00E-09</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Calu3 human lung carcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>IC-50</td>
<td></td>
<td>1.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>ARN-398</td>
<td>Ceramidase (nonspecified) inhibition, IN VITRO</td>
<td>Acid Ceramidase (ACDase; ASAH1) Inhibitors</td>
<td>Ceramidase (nonspecified)</td>
<td></td>
<td>Rat enzyme</td>
<td>IC-50</td>
<td></td>
<td>1.20E-08</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK1</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-90</td>
<td></td>
<td>1.25E-08</td>
<td>M</td>
</tr>
<tr>
<td>Lycorine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Dye assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>1.57E-08</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK1</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-99</td>
<td></td>
<td>1.76E-08</td>
<td>M</td>
</tr>
<tr>
<td>Noscapine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Tubulin Polymerization Inhibitors;Apoptosis Inducers;Antimitotic Drugs</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-90</td>
<td></td>
<td>2.20E-08</td>
<td>g/l</td>
</tr>
<tr>
<td>Carmofur</td>
<td>Ceramidase (nonspecified) inhibition, IN VITRO</td>
<td>Thymidylate Synthase Inhibitors;Pyrimidine Antagonists</td>
<td>Ceramidase (nonspecified)</td>
<td></td>
<td>Rat enzyme</td>
<td>IC-50</td>
<td></td>
<td>2.90E-08</td>
<td>M</td>
</tr>
<tr>
<td>JMF-1507</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>3.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Inflammatory disorders remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Inflammatory disorders</td>
<td>ELISA assay</td>
<td>RAW264.7 mouse macrophages</td>
<td>MIC</td>
<td>&lt;=</td>
<td>3.13E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>MiaPaCa2 human pancreas adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.80E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pyrazofurin</td>
<td>Nephrotoxicity induction, IN VITRO</td>
<td>Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors</td>
<td>Nephrotoxicity</td>
<td>Cell viability assay</td>
<td>Vero African green monkey kidney cells</td>
<td>CC-50</td>
<td></td>
<td>5.20E-08</td>
<td>g/l</td>
</tr>
<tr>
<td>TG-0205221</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>5.30E-08</td>
<td>M</td>
</tr>
<tr>
<td>JMF-1507</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>6.00E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>IL-2 Receptor Complex antagonism, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>IL-2 Receptor Complex</td>
<td>Thymidine incorporation assay</td>
<td>T-Lymphocytes (spleen), mouse</td>
<td>MIC</td>
<td>&lt;=</td>
<td>6.25E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Inflammatory disorders remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Inflammatory disorders</td>
<td>Nitrite assay</td>
<td>RAW264.7 mouse macrophages</td>
<td>MIC</td>
<td></td>
<td>6.25E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>MiaPaCa2 human pancreas adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.39E-08</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td></td>
<td>Epithelial cells (airway), human</td>
<td>IC-50</td>
<td></td>
<td>6.90E-08</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Epithelial cells (airway), human</td>
<td>IC-50</td>
<td></td>
<td>6.90E-08</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas</td>
<td>Cell counting assay</td>
<td>CFPAC1 human pancreas cancer cells</td>
<td>CC-50</td>
<td></td>
<td>7.70E-08</td>
<td>M</td>
</tr>
<tr>
<td>Niclosamide</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Cytochrome P450 CYP1A2 Inhibitors;Quorum Sensing (Pseudomonas aeruginosa) Inhibitors;Neuropeptide Y4 (NPY Y4) Receptor Positive Allosteric Modulators;Autophagy Inducers;Wnt Signaling Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td>&lt;</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cytotoxicity</td>
<td>Dye assay (alamar blue)</td>
<td>MRC5 human embryonic lung fibroblasts</td>
<td>CC-50</td>
<td></td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Tumor Necrosis Factor (TNF-alpha) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Tumor Necrosis Factor (TNF-alpha)</td>
<td>Chemiluminescent assay</td>
<td>BV2 murine microglia cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cancer, mouth (squamous cell) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cancer, mouth (squamous cell)</td>
<td>Dye assay (alamar blue)</td>
<td>HSC3 human oral squamous cell carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Dye assay (MTT) @ 72 h</td>
<td>HCT116 human colon carcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (MTT) @ 72 h</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>6',6'-Difluoroaristeromycin</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>S-Adenosyl-L-Homocysteine Hydrolase Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Plaque assay</td>
<td>VeroE6 African green monkey kidney cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>BxPC3 human pancreas adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>1.03E-07</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK2</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-90</td>
<td></td>
<td>1.08E-07</td>
<td>M</td>
</tr>
<tr>
<td>Azithromycin</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Nonsense Mutation Suppressors;50S Ribosomal Protein Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Luciferine/luciferase assay</td>
<td>HEK293T human embryonic kidney cells transfected with luciferase</td>
<td>IC-50</td>
<td></td>
<td>1.10E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Cell counting assay</td>
<td>Pancreatic ductal epithelial cells, human</td>
<td>CC-50</td>
<td></td>
<td>1.11E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Cell counting assay</td>
<td>Pancreatic ductal epithelial cells, human</td>
<td>CC-50</td>
<td></td>
<td>1.11E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>NF-kappaB (NFkB) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>NF-kappaB (NFkB)</td>
<td>Gene reporter assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.25E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Inflammatory disorders remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Inflammatory disorders</td>
<td>ELISA assay</td>
<td>RAW264.7 mouse macrophages</td>
<td>MIC</td>
<td></td>
<td>1.25E-07</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Dihydroorotate Dehydrogenase (quinone), mitochondrial  (DHODH) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Dihydroorotate Dehydrogenase (quinone), mitochondrial  (DHODH)</td>
<td>2,6-dichlorophenolindophenol reduction assay</td>
<td>Recombinant human enzyme</td>
<td>IC-50</td>
<td></td>
<td>1.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>TG-0205221</td>
<td>Coronavirus acute respiratory syndrome remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>Coronavirus acute respiratory syndrome</td>
<td>Plaque assay</td>
<td>MRC5 human embryonic lung fibroblasts</td>
<td>IC-50</td>
<td></td>
<td>1.40E-07</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK2</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-99</td>
<td></td>
<td>1.49E-07</td>
<td>M</td>
</tr>
<tr>
<td>JMF-1521</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>1.80E-07</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK1</td>
<td>Nephrotoxicity induction, IN VITRO</td>
<td></td>
<td>Nephrotoxicity</td>
<td>Dye assay</td>
<td>Vero African green monkey kidney cells</td>
<td>CC-50</td>
<td></td>
<td>1.91E-07</td>
<td>M</td>
</tr>
<tr>
<td>Remdesivir</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Nucleobindin-1 (NUCB1) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>2.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Leukemia, acute promyelocytic (M3) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Leukemia, acute promyelocytic (M3)</td>
<td>Dye assay (MTT)</td>
<td>HL60 human acute promyelocytic leukemia cells</td>
<td>CC-50</td>
<td></td>
<td>2.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Matrigel-coated plate assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Spheres formation assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Colony formation assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Monoglyceride Lipase inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Monoglyceride Lipase</td>
<td>2-Oleoylglycerol as substrate</td>
<td>Recombinant human enzyme</td>
<td>IC-50</td>
<td></td>
<td>2.04E-07</td>
<td>M</td>
</tr>
<tr>
<td>N-3</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>MCA-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-lys(Dnp)-lys-NH2 as substrate</td>
<td>Coronavirus</td>
<td>Ki</td>
<td></td>
<td>2.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>NF-kappaB (NFkB) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>NF-kappaB (NFkB)</td>
<td>Gene reporter assay</td>
<td>Mel270 human uveal melanoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>NF-kappaB (NFkB) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>NF-kappaB (NFkB)</td>
<td>Gene reporter assay</td>
<td>OMM2.3 human uveal melanoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>MMP-9 (Gelatinase B) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>MMP-9 (Gelatinase B)</td>
<td></td>
<td>92.1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Inflammatory disorders remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Inflammatory disorders</td>
<td>ELISA assay</td>
<td>RAW264.7 mouse macrophages</td>
<td>MIC</td>
<td></td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Wound closure assay</td>
<td>92.1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Transwell chamber assay</td>
<td>92.1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Transwell chamber assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Transwell chamber assay</td>
<td>92.1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Transwell chamber assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>N-3</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>MCA-Ala-Val-Leu-Gln-Ser-Gly-Phe-Arg-lys(Dnp)-lys-NH2 as substrate</td>
<td>Coronavirus</td>
<td>Ki</td>
<td></td>
<td>2.60E-07</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>GABA(A) BZ Site Receptor affinity, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>GABA(A) BZ Site Receptor</td>
<td>Displacement of [3H]-flunitrazepam</td>
<td>Brain, rat</td>
<td>Ki</td>
<td></td>
<td>2.60E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Tumor Necrosis Factor Ligand Superfamily Member 11 (TNFSF11, RANKL) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Tumor Necrosis Factor Ligand Superfamily Member 11 (TNFSF11, RANKL)</td>
<td>RNA assay</td>
<td>Fibroblasts (synovial), rat (arthritic)</td>
<td>MIC</td>
<td></td>
<td>3.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>BTB-06256</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td></td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>GRL-0667</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.20E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, cervix, (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, cervix, (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>HeLa human cervix adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>3.20E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>ATP assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>3.80E-07</td>
<td>M</td>
</tr>
<tr>
<td>Sinefungin</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.83E-07</td>
<td>M</td>
</tr>
<tr>
<td>Noscapine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Tubulin Polymerization Inhibitors;Apoptosis Inducers;Antimitotic Drugs</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cell counting assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>4.00E-07</td>
<td>g/l</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Tyrosinase (Tyr) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Tyrosinase (Tyr)</td>
<td>Thiouracil incorporation assay</td>
<td>Melanocytes, human</td>
<td>IC-50</td>
<td></td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Hepatoblastoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Hepatoblastoma</td>
<td>Dye assay (alamar blue)</td>
<td>HepG2 human hepatoblastoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Leukemia, acute promyelocytic (M3) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Leukemia, acute promyelocytic (M3)</td>
<td>Dye assay (alamar blue)</td>
<td>HL60 human acute promyelocytic leukemia cells</td>
<td>CC-50</td>
<td></td>
<td>4.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Baicalein</td>
<td>ATP-Dependent DNA Helicases inhibition, IN VITRO</td>
<td>Drugs Targeting on Quorum Sensing Signaling;Signal Transduction Modulators;AR Expression Inhibitors;15-Lipoxygenase Inhibitors;Autophagy Inducers;12-Lipoxygenase Inhibitors;Dual Specificity Protein Phosphatase 3 (VHR) Inhibitors;Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;Apoptosis Inducers;Protein Tyrosine Phosphatase (PTP) Inhibitors</td>
<td>ATP-Dependent DNA Helicases</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.70E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Flow cytometry assay</td>
<td>HEK293 human embryonic kidney cells (ABCB1-overexpressing)</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Hypoxia Inducible Factor 1-alpha (HIF-1alpha) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Hypoxia Inducible Factor 1-alpha (HIF-1alpha)</td>
<td>ELISA assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype)</td>
<td>ELISA assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>MAC-5576</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Catenin beta-1 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Catenin beta-1</td>
<td>Chemiluminescent assay</td>
<td>Hippocampus (dorsal), mouse (beta-amyloid (42)-treated)</td>
<td>MEC</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Glycogen Synthase Kinase 3 beta (GSK-3beta) induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Glycogen Synthase Kinase 3 beta (GSK-3beta)</td>
<td>Chemiluminescent assay</td>
<td>Hippocampus (dorsal), mouse (beta-amyloid (42)-treated)</td>
<td>MEC</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Survivin (BIRC5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Survivin (BIRC5)</td>
<td>RNA assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>MMP-9 (Gelatinase B) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>MMP-9 (Gelatinase B)</td>
<td></td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-9 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-9</td>
<td>Acetyl-LEHD-p-nitroaniline as a substrate</td>
<td>COLO205 human colon carcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-8 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-8</td>
<td>Acetyl-IETD-p-nitroaniline as a substrate</td>
<td>COLO205 human colon carcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>PC3 human prostate adenocarcinoma cells (hypoxic)</td>
<td>MCC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Leukemia, acute promyelocytic (M3) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Leukemia, acute promyelocytic (M3)</td>
<td>Dye assay (MTT)</td>
<td>HL60 human acute promyelocytic leukemia cells</td>
<td>CC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (alamar blue)</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Leukemia, myeloid remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Leukemia, myeloid</td>
<td>Dye assay (alamar blue)</td>
<td>K562 human myeloid leukemia cells</td>
<td>CC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Melanoma, metastatic remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Melanoma, metastatic</td>
<td>Dye assay (alamar blue)</td>
<td>B16F10 mouse metastatic melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Wound closure assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Propidium iodide assay</td>
<td>HCT116 human colon carcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Propidium iodide assay</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Propidium iodide assay</td>
<td>COLO205 human colon carcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Flow cytometry assay</td>
<td>Mitochondria (COLO205 human colon carcinoma cells)</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>6',6'-Difluoroaristeromycin</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>S-Adenosyl-L-Homocysteine Hydrolase Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Dye assay (MTS)</td>
<td>VeroE6 African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>5.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>JMF-1521</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td></td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>5.20E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, rhinopharyngeal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, rhinopharyngeal</td>
<td>Dye assay (MTT)</td>
<td>KBv200 human epidermoid carcinoma cells (multidrug-resistant/ABCB1-overexpressing)</td>
<td>CC-50</td>
<td></td>
<td>5.20E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, rhinopharyngeal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, rhinopharyngeal</td>
<td>Dye assay (MTT)</td>
<td>KB human epidermoid rhinopharyngeal carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>5.40E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma</td>
<td></td>
<td>MDAMB435 human melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>5.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>GRL-0617</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.60E-07</td>
<td>M</td>
</tr>
<tr>
<td>TG-0205221</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (alamar blue)</td>
<td>Mononuclear cells (blood), human</td>
<td>CC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>GRL-0617</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Ubiquitin-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>GC-373</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>3C-Like Protease (Norovirus) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cancer, colon</td>
<td>Dye assay (alamar blue)</td>
<td>HCT116 human colon carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cancer, mouth (squamous cell) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cancer, mouth (squamous cell)</td>
<td>Dye assay (alamar blue)</td>
<td>SCC4 human oral squamous cell carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Dye assay (MTS)</td>
<td>MiaPaCa2 human pancreas adenocarcinoma cells</td>
<td>MCC</td>
<td>&lt;=</td>
<td>6.25E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>PANC1 human pancreas adenocarcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>6.25E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MiaPaCa2 human pancreas adenocarcinoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>6.25E-07</td>
<td>M</td>
</tr>
<tr>
<td>Betulonic acid</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Lysosomal alpha-Glucosidase (GAA) Inhibitors;E3 Ubiquitin-Protein Ligase Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>6.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, stomach (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, stomach (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>SGC7901 human gastric adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>6.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>GRL-0667</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>6.70E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>HEK293 human embryonic kidney cells</td>
<td>CC-50</td>
<td></td>
<td>6.90E-07</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, herpes simplex virus remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Signal Transduction Modulators;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, herpes simplex virus</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>7.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Tanshinone I</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;AP-1 Transcription Factor Complex Inhibitors;Aryl Hydrocarbon Receptor (AhR) Ligands</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Ubiquitin-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>7.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>ATP assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>7.50E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Hepatoblastoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Hepatoblastoma</td>
<td>Dye assay (MTT)</td>
<td>HepG2 human hepatoblastoma cells</td>
<td>IC-50</td>
<td></td>
<td>7.80E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Spheres formation assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent) (mammospheres)</td>
<td>MIC</td>
<td></td>
<td>7.80E-07</td>
<td>M</td>
</tr>
<tr>
<td>Iguesterin</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>8.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Dye assay (MTT) @ 48 h</td>
<td>COLO205 human colon carcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>8.40E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>8.70E-07</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Malaria</td>
<td></td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>9.00E-07</td>
<td>M</td>
</tr>
<tr>
<td>Geldanamycin</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>9.10E-07</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>HEK293 human embryonic kidney cells (ABCB1-overexpressing)</td>
<td>CC-50</td>
<td></td>
<td>9.30E-07</td>
<td>M</td>
</tr>
<tr>
<td>NSC-158362</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>MA104 embryonic African green monkey kidney cells</td>
<td>IC-50</td>
<td>&lt;</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>NSC-158362</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td>&lt;</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Flow cytometry assay</td>
<td>HEK293 human embryonic kidney cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>Nephrotoxicity induction, IN VITRO</td>
<td>Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors;Equilibrative Nucleoside Transporter ENT1 Inhibitors</td>
<td>Nephrotoxicity</td>
<td>Cell viability assay</td>
<td>Vero African green monkey kidney cells</td>
<td>CC-50</td>
<td>&gt;</td>
<td>1.00E-06</td>
<td>g/l</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTS)</td>
<td>RAW264.7 mouse macrophages</td>
<td>MCC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTS)</td>
<td>RAW264.7 mouse macrophages</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>Macrophage cells (bone marrow), mouse</td>
<td>MCC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Sphingosine Kinase 1 (SPK1) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Sphingosine Kinase 1 (SPK1)</td>
<td>ELISA assay</td>
<td>PC3 human prostate adenocarcinoma cells (hypoxic)</td>
<td>MIC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Interleukin-6 (IL-6) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Interleukin-6 (IL-6)</td>
<td>Chemiluminescent assay</td>
<td>BV2 murine microglia cells</td>
<td>MIC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Multidrug Resistance Protein 1 (MDR-1) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Multidrug Resistance Protein 1 (MDR-1)</td>
<td>Flow cytometry assay</td>
<td>HEK293 human embryonic kidney cells (ABCB1-overexpressing)</td>
<td>MIC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>DNA Topoisomerase II (nonspecified subtype) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>DNA Topoisomerase II (nonspecified subtype)</td>
<td>DNA relaxation assay</td>
<td>Human enzyme</td>
<td>IC-50</td>
<td>&gt;</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>5-Hydroxytryptamine Receptor 1A (5-HT1A) agonism, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>5-Hydroxytryptamine Receptor 1A (5-HT1A)</td>
<td>Chemiluminescent assay</td>
<td>Cortical neurons (primary), mouse</td>
<td>MEC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>JMF-1521</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td></td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Survivin (BIRC5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Survivin (BIRC5)</td>
<td>RNA assay</td>
<td>92.1 human uveal melanoma cells</td>
<td>MIC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-3 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-3</td>
<td>Acetyl-DEVD-p-nitroaniline as a substrate</td>
<td>HCT116 human colon carcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-3 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-3</td>
<td>Acetyl-DEVD-p-nitroaniline as a substrate</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-3 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-3</td>
<td>Acetyl-DEVD-p-nitroaniline as a substrate</td>
<td>COLO205 human colon carcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-9 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-9</td>
<td>Acetyl-LEHD-p-nitroaniline as a substrate</td>
<td>HCT116 human colon carcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-9 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-9</td>
<td>Acetyl-LEHD-p-nitroaniline as a substrate</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-8 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-8</td>
<td>Acetyl-IETD-p-nitroaniline as a substrate</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MCC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Neuroinflammation remission/reduction, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Neuroinflammation</td>
<td>Nitrite assay</td>
<td>BV2 murine microglia cells</td>
<td>MIC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Flow cytometry assay</td>
<td>92.1 human uveal melanoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Flow cytometry assay</td>
<td>OMM1 human uveal melanoma cells</td>
<td>MEC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Dementia, Alzheimer type protection, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Dementia, Alzheimer type</td>
<td>Dye assay (MTT)</td>
<td>SHSY5Y human dopaminergic neuroblastoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MDAMB231 human breast adenocarcinoma cells (ALDH-positive)</td>
<td>MCC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Osteoporosis remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Osteoporosis</td>
<td>Spectrophotometric assay</td>
<td>Macrophage cells (bone marrow), mouse</td>
<td>IC-50</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cytotoxicity remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>hFOB1.19 human fetal osteoblasts (SV40 large Tantigen-transformed)</td>
<td>MCC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cytotoxicity remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>hFOB1.19 human fetal osteoblasts (SV40 large Tantigen-transformed)</td>
<td>MCC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT) @ 72 h</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Flow cytometry assay</td>
<td>Mitochondria (HCT116 human colon carcinoma cells)</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>Mitochondria (SW620 human colon adenocarcinoma cells)</td>
<td>MEC</td>
<td></td>
<td>1.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Mucroporin-M1</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>Cell Membrane Disrupting Agents</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>MDBK Madin-Darby bovine kidney epithelial cells</td>
<td>CC-50</td>
<td></td>
<td>1.03E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Estrogen Receptor alpha (ERalpha) affinity, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Estrogen Receptor alpha (ERalpha)</td>
<td>Displacement of [3H]-estradiol</td>
<td>Recombinant human receptor</td>
<td>IC-50</td>
<td></td>
<td>1.03E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Dye assay (MTT)</td>
<td>A549 human non-small-cell lung carcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>1.03E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (MTT) @ 48 h</td>
<td>SW620 human colon adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>1.04E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>G-Protein Coupled Bile Acid Receptor BG37 (TGR5) agonism, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>G-Protein Coupled Bile Acid Receptor BG37 (TGR5)</td>
<td>Gene reporter assay</td>
<td>CHO Chinese hamster ovary cells transfected with human GPBA (TGR5) receptor</td>
<td>EC-50</td>
<td></td>
<td>1.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Dye assay (MTS)</td>
<td>92.1 human uveal melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>1.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>(-)-Savinin</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>1.13E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, liver (hepatocellular carcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, liver (hepatocellular carcinoma)</td>
<td>Dye assay (MTT)</td>
<td>BEL7402 human hepatocellular carcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>1.16E-06</td>
<td>M</td>
</tr>
<tr>
<td>DTPMPA</td>
<td>ATPase (nonspecified subtype) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>ATPase (nonspecified subtype)</td>
<td>Phosphate release assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.19E-06</td>
<td>M</td>
</tr>
<tr>
<td>Dihydrotan</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Hypoxia Inducible Factor 1-alpha (HIF-1alpha) Inhibitors;Immune Checkpoint Inhibitors;Indoleamine 2,3-dioxygenase 1 (IDO1; IDO) Inhibitors;Acetylcholinesterase (AChE) Inhibitors;Nitric Oxide (NO) Production Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Ubiquitin-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, colon remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, colon</td>
<td>Dye assay (MTT) @ 48 h</td>
<td>HCT116 human colon carcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>1.22E-06</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK3</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-90</td>
<td></td>
<td>1.23E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, pancreas (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, pancreas (adenocarcinoma)</td>
<td>Dye assay (MTS)</td>
<td>PANC1 human pancreas adenocarcinoma cells</td>
<td>MCC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, endometrium (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, endometrium (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MDAH2774 human endometrium adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate</td>
<td>Dye assay (MTS)</td>
<td>LNCaP human prostate carcinoma cells (androgen-dependent)</td>
<td>MCC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Dye assay (MTS)</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MCC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate</td>
<td>Flow cytometry assay</td>
<td>LNCaP human prostate carcinoma cells (androgen-dependent)</td>
<td>MEC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, prostate (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, prostate (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>1.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Sarcoma, synovial remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Sarcoma, synovial</td>
<td>Dye assay (MTT)</td>
<td>SW982 human synovial sarcoma cells</td>
<td>CC-50</td>
<td></td>
<td>1.28E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Malaria</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>1.33E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Dihydroorotate Dehydrogenase (quinone), mitochondrial  (DHODH) affinity, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Dihydroorotate Dehydrogenase (quinone), mitochondrial  (DHODH)</td>
<td>Isothermal microcalorimetric test</td>
<td>Recombinant human enzyme</td>
<td>Kd</td>
<td></td>
<td>1.33E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Cytopathicity assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>1.39E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferroquine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td></td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>Antigen assay</td>
<td>H9 human T-cell leukemia cells</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>Viral replication assay</td>
<td>H9 human T-cell leukemia cells</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Fatty acid oxidation disorders remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Fatty acid oxidation disorders</td>
<td>TBARS formation assay</td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>Viral replication assay</td>
<td>H9 human T-cell leukemia cells</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>Viral replication assay</td>
<td>H9 human T-cell leukemia cells</td>
<td>IC-50</td>
<td></td>
<td>1.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Cancer remission/reduction, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Cancer</td>
<td></td>
<td>Endothelial cells (lymphatic), rat (temperature-sensitive)</td>
<td>IC-50</td>
<td></td>
<td>1.41E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Signal Transduction Modulators;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Malaria</td>
<td>Fluorescent assay</td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>1.42E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;Apoptosis Inducers;NF-kappaB (NFKB) Activators;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Malaria</td>
<td>Fluorescent assay</td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>1.42E-06</td>
<td>M</td>
</tr>
<tr>
<td>ML-188</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>ML-188</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Osteoporosis remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Osteoporosis</td>
<td>Tartrate-resistant acid phosphatase assay</td>
<td>Macrophage cells (bone marrow), mouse</td>
<td>IC-50</td>
<td></td>
<td>1.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Sinefungin</td>
<td>RNA (Guanine-7-) Methyltransferase inhibition, IN VITRO</td>
<td>Coactivator Associated Arginine Methyltransferase 1 (CARM1; PRMT4) Inhibitors;Histone-Lysine N-Methyltransferase SETD7 (SET7/9) Inhibitors;Protein-L-Isoaspartate(D-Aspartate) O-Methyltransferase (PCMT1; PIMT) Inhibitors;Epigenetic Modifier Modulators</td>
<td>RNA (Guanine-7-) Methyltransferase</td>
<td>Yeast-based assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>1.62E-06</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK3</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-99</td>
<td></td>
<td>1.63E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>alpha-1 Adrenergic Receptors (nonspecified subtype) antagonism, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>alpha-1 Adrenergic Receptors (nonspecified subtype)</td>
<td></td>
<td>Artery (aorta, thoracic), rat</td>
<td>IC-50</td>
<td></td>
<td>1.67E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Dye assay (MTS)</td>
<td>Mel270 human uveal melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>1.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, stomach remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, stomach</td>
<td>Colony formation assay</td>
<td>GES-1 human gastric epithelial cells (methyl-N-nitroso-guanidine-treated)</td>
<td>IC-50</td>
<td></td>
<td>1.72E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>ATP assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent) (mammospheres)</td>
<td>CC-50</td>
<td></td>
<td>1.75E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Estrogen Receptor (nonspecified subtype) agonism, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Estrogen Receptor (nonspecified subtype)</td>
<td>Luciferine/luciferase assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>EC-50</td>
<td></td>
<td>1.85E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Aldo-Keto Reductase Family 1 Member B10 (ARL-1) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Aldo-Keto Reductase Family 1 Member B10 (ARL-1)</td>
<td>Fluorescent assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>2.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Caspase-8 activation, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Caspase-8</td>
<td>Acetyl-IETD-p-nitroaniline as a substrate</td>
<td>HCT116 human colon carcinoma cells</td>
<td>MEC</td>
<td></td>
<td>2.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Flow cytometry assay</td>
<td>Mel270 human uveal melanoma cells</td>
<td>MEC</td>
<td></td>
<td>2.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Flow cytometry assay</td>
<td>OMM2.3 human uveal melanoma cells</td>
<td>MEC</td>
<td></td>
<td>2.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Dye assay (MTS)</td>
<td>OMM1 human uveal melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>2.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>Ferricytochrome c reduction assay</td>
<td>Neutrophils, human</td>
<td>IC-50</td>
<td></td>
<td>2.23E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>G-Protein Coupled Bile Acid Receptor BG37 (TGR5) agonism, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>G-Protein Coupled Bile Acid Receptor BG37 (TGR5)</td>
<td>cAMP accumulation assay</td>
<td>HEK293 human embryonic kidney cells transfected with human GPBA (TGR5) receptor</td>
<td>EC-50</td>
<td></td>
<td>2.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Kaempferol 3-O-alpha-L-arabinofuranoside</td>
<td>Hypothetical Protein Sars3a inhibition, IN VITRO</td>
<td>Hedgehog Signaling Inhibitors;Antioxidants</td>
<td>Hypothetical Protein Sars3a</td>
<td>Voltage-clamp assay (-60 mV)</td>
<td>Oocytes (Xenopus) transfected with SARS associated coronavirus 3a protein</td>
<td>IC-50</td>
<td></td>
<td>2.30E-06</td>
<td>M</td>
</tr>
<tr>
<td>Bananin</td>
<td>ATPase (nonspecified subtype) inhibition, IN VITRO</td>
<td>Chelating Agents</td>
<td>ATPase (nonspecified subtype)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>2.30E-06</td>
<td>M</td>
</tr>
<tr>
<td>Dieckol</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;beta-Secretase 1 (BACE1) Inhibitors;Acetylcholinesterase (AChE) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>2.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Osteoporosis remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Osteoporosis</td>
<td></td>
<td>Macrophage cells (bone marrow), mouse</td>
<td>IC-50</td>
<td>&lt;=</td>
<td>2.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>SKBr3 human breast adenocarcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>CC-50</td>
<td></td>
<td>2.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Signal Transducer and Activator of Transcription 3 (STAT3) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Signal Transducer and Activator of Transcription 3 (STAT3)</td>
<td>Luciferine/luciferase assay</td>
<td>Hep3B human hepatocellular carcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>2.45E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Malaria</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>2.47E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>HIV-1 Protease inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>HIV-1 Protease</td>
<td></td>
<td>HIV</td>
<td>IC-50</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Zinc Finger and BTB Domain Containing 10 induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Zinc Finger and BTB Domain Containing 10</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>SP Transcritption Factors inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>SP Transcritption Factors</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>MicroRNA 27a inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>MicroRNA 27a</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Vascular Endothelial Growth Factors (VEGF) (nonspecified subtype) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Vascular Endothelial Growth Factors (VEGF) (nonspecified subtype)</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Vascular Endothelial Growth Factor Receptor (VEGFR) (nonspecified subtype) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Vascular Endothelial Growth Factor Receptor (VEGFR) (nonspecified subtype)</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, ovary remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, ovary</td>
<td>Flow cytometry assay</td>
<td>OVCAR5 human ovary carcinoma cells</td>
<td>MEC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, ovary remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, ovary</td>
<td>Flow cytometry assay</td>
<td>Mitochondria (OVCAR5 human ovary carcinoma cells)</td>
<td>MEC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, endometrium (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, endometrium (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>Mitochondria (MDAH2774 human endometrium adenocarcinoma cells)</td>
<td>MEC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>MEC</td>
<td>&lt;=</td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast</td>
<td>Cell counting assay</td>
<td>MDAMB453 human breast carcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Melanoma</td>
<td>Cell counting assay</td>
<td>MDAMB435 human melanoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast</td>
<td>Cell counting assay</td>
<td>MDAMB453 human breast carcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast</td>
<td>Cell counting assay</td>
<td>MDAMB468 human breast carcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast</td>
<td>Cell counting assay</td>
<td>Hs578T human breast carcinoma cells</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (in situ ductal carcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (in situ ductal carcinoma)</td>
<td>Cell counting assay</td>
<td>BT474 human breast ductal carcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>MIC</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Glioma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Glioma</td>
<td>Dye assay (MTT)</td>
<td>C6 rat glioma cells</td>
<td>CC-50</td>
<td></td>
<td>2.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Iguesterin</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>2.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Dieckol</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>Reverse Transcriptase/Ribonuclease H (HIV-1) Inhibitors;beta-Secretase 1 (BACE1) Inhibitors;Acetylcholinesterase (AChE) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>2.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Malaria</td>
<td></td>
<td></td>
<td>IC-50</td>
<td></td>
<td>2.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, mouth (squamous cell) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, mouth (squamous cell)</td>
<td>Dye assay (alamar blue)</td>
<td>HSC3 human oral squamous cell carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>2.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, uveal remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, uveal</td>
<td>Dye assay (MTS)</td>
<td>OMM2.3 human uveal melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>2.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Hirsutenone</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;LDL Antioxidants;Signal Transduction Modulators;Antiinflammatory Drugs;Free Radical Scavengers;Nitric Oxide (NO) Production Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Ubiquitin-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Bananin</td>
<td>ATP-Dependent DNA Helicases inhibition, IN VITRO</td>
<td>Chelating Agents</td>
<td>ATP-Dependent DNA Helicases</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>3.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Dye assay (MTT)</td>
<td>A549 human non-small-cell lung carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>3.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>3.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Leukemia, myeloid remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Leukemia, myeloid</td>
<td></td>
<td>K562 human myeloid leukemia cells</td>
<td>CC-50</td>
<td></td>
<td>3.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>HLA Class I Histocompatibility antigen, B-7 alpha chain (HLA-B) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>HLA Class I Histocompatibility antigen, B-7 alpha chain (HLA-B)</td>
<td>Luciferine/luciferase assay</td>
<td>HeLa human cervix adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>3.25E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>HT29 human colon adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>3.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, cervix, (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, cervix, (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>HeLa human cervix adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>3.42E-06</td>
<td>M</td>
</tr>
<tr>
<td>GC-373</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (Norovirus) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.48E-06</td>
<td>M</td>
</tr>
<tr>
<td>GC-373</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (Norovirus) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.48E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Protein Tyrosine Phosphatase 1B (PTP-1B) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Protein Tyrosine Phosphatase 1B (PTP-1B)</td>
<td>p-Nitrophenyl phosphate as substrate</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>3.49E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cytotoxicity</td>
<td>Dye assay (alamar blue)</td>
<td>MRC5 human embryonic lung fibroblasts</td>
<td>CC-50</td>
<td></td>
<td>3.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Lysosomal alpha-Glucosidase inhibition, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Lysosomal alpha-Glucosidase</td>
<td>p-Nitrophenyl alpha-D-glucopyranoside as substrate</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>3.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Mucroporin-M1</td>
<td>Influenza A remission/reduction, IN VITRO</td>
<td>Cell Membrane Disrupting Agents</td>
<td>Influenza A</td>
<td>Plaque assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>3.52E-06</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK2</td>
<td>Nephrotoxicity induction, IN VITRO</td>
<td></td>
<td>Nephrotoxicity</td>
<td>Dye assay</td>
<td>Vero African green monkey kidney cells</td>
<td>CC-50</td>
<td></td>
<td>3.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Signal Transduction Modulators;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, cytomegalovirus</td>
<td>Fluorescent assay</td>
<td>Fibroblasts (foreskin), human</td>
<td>IC-50</td>
<td></td>
<td>3.62E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, cytomegalovirus remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;Apoptosis Inducers;NF-kappaB (NFKB) Activators;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, cytomegalovirus</td>
<td>Fluorescent assay</td>
<td>Fibroblasts (foreskin), human</td>
<td>IC-50</td>
<td></td>
<td>3.62E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Estrogen Receptor alpha (ERalpha) agonism, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Estrogen Receptor alpha (ERalpha)</td>
<td>Luciferine/luciferase assay</td>
<td>CV1 African green monkey kidney fibroblasts transfected with ERalpha receptor</td>
<td>EC-50</td>
<td></td>
<td>3.68E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Signal Transduction Modulators;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Malaria</td>
<td>Radioactivity assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>3.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Papyriflavonol A</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;Phospholipase A2 (PLA2) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>3.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Noscapine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Tubulin Polymerization Inhibitors;Apoptosis Inducers;Antimitotic Drugs</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Dye assay (neutral red)</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>3.80E-06</td>
<td>g/l</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>RWPE1 human prostate epithelial cells</td>
<td>MCC</td>
<td></td>
<td>4.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Tingenone</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Antioxidants;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs;Free Radical Scavengers</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>4.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Cancer, prostate remission/reduction, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Cancer, prostate</td>
<td>Bromodeoxyuridine incorporation assay</td>
<td>Epithelial cells (prostate), human (cadmium-transformed)</td>
<td>MIC</td>
<td></td>
<td>4.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Apoptosis Inducers</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>4.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Apoptosis Inducers</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Dye assay (MTS)</td>
<td>VeroE6 African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>4.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Chloroquine phosphate</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Apoptosis Inducers</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>4.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Hirsutenone</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;LDL Antioxidants;Signal Transduction Modulators;Antiinflammatory Drugs;Free Radical Scavengers;Nitric Oxide (NO) Production Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Hirsutenone</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;LDL Antioxidants;Signal Transduction Modulators;Antiinflammatory Drugs;Free Radical Scavengers;Nitric Oxide (NO) Production Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>ML-300</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.11E-06</td>
<td>M</td>
</tr>
<tr>
<td>(-)-Savinin</td>
<td>Cancer, ovary (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</td>
<td>Cancer, ovary (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SKOV3 human ovary adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.16E-06</td>
<td>M</td>
</tr>
<tr>
<td>Tripterin</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;Heat Shock Protein 90 (Hsp90) Inhibitors;Lipid Peroxidation Inhibitors;Cytokine Production Inhibitors;Apoptosis Inducers;Enoyl-(Acyl Carrier Protein) Reductase (FabI) (Plasmodium falciparum) Inhibitors;Antioxidants;Myc Proto-Oncogene Protein (c-Myc)/Myc-Associated Factor X (Max) Interaction Inhibitors</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>4.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>GC-376</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (Norovirus) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.35E-06</td>
<td>M</td>
</tr>
<tr>
<td>GC-376</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>3C-Like Protease (Norovirus) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>4.35E-06</td>
<td>M</td>
</tr>
<tr>
<td>(-)-Savinin</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</td>
<td>Melanoma</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SKMEL2 human melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.37E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Glioblastoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Glioblastoma</td>
<td>Dye assay (MTT)</td>
<td>U251 human glioblastoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>HeLa human cervix adenocarcinoma cells (CD4+/CCR5+) transfected with HIV-1 LTRbeta-gal-positive</td>
<td>CC-50</td>
<td></td>
<td>4.52E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cytotoxicity induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cytotoxicity</td>
<td>Dye assay (MTT)</td>
<td>HeLa human cervix adenocarcinoma cells (CD4+/CCR5+) transfected with HIV-1 LTRbeta-gal-positive</td>
<td>CC-50</td>
<td></td>
<td>4.52E-06</td>
<td>M</td>
</tr>
<tr>
<td>Xanthoangelol B</td>
<td>Anemia, hemolytic remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Cysteine Protease Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants;Sensor Histidine Kinase (Bacterial) Inhibitors;Plasminogen Activator Inhibitor (PAI-1) Inhibitors;Nitric Oxide (NO) Production Inhibitors;Free Radical Scavengers</td>
<td>Anemia, hemolytic</td>
<td></td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>4.62E-06</td>
<td>M</td>
</tr>
<tr>
<td>(-)-Savinin</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>HCT15 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>4.82E-06</td>
<td>M</td>
</tr>
<tr>
<td>Imatinib mesylate</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Tyrosine-Protein Kinase ABL1 Inhibitors;Bcr-Abl (Bcr-Abl1) Kinase Inhibitors;PDGFRalpha Inhibitors;PDGFRbeta Inhibitors;Signal Transduction Modulators;Breast Cancer-Resistant Protein (BCRP; ABCG2) Inhibitors;KIT (C-KIT) Inhibitors;CSF1R (c-FMS) Inhibitors;Apoptosis Inducers;Angiogenesis Inhibitors</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>RNA assay</td>
<td>Calu3 human lung carcinoma cells (c-erbB2-overexpressing)</td>
<td>MIC</td>
<td>&gt;</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>DNA Topoisomerase II alpha inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>DNA Topoisomerase II alpha</td>
<td>DNA decatenation assay</td>
<td>Human enzyme</td>
<td>IC-50</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Activity-Regulated Cytoskeleton-Associated Protein activation, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Activity-Regulated Cytoskeleton-Associated Protein</td>
<td>RNA assay</td>
<td>Cortical neurons (primary), mouse</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Early Growth Response 1 (EGR1) induction, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Early Growth Response 1 (EGR1)</td>
<td>RNA assay</td>
<td>Cortical neurons (primary), mouse</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Caveolin 1 (CAV1) induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Caveolin 1 (CAV1)</td>
<td>Chemiluminescent assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>L-Lactate Dehydrogenase A chain (LDH-A) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>L-Lactate Dehydrogenase A chain (LDH-A)</td>
<td>Chemiluminescent assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1)</td>
<td>Chemiluminescent assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1)</td>
<td>Chemiluminescent assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>[Pyruvate Dehydrogenase (Acetyl-Transferring)] Kinase isozyme 1, mitochondrial (PDK1)</td>
<td>Chemiluminescent assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Transcription Factor p65 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Transcription Factor p65</td>
<td>Chemiluminescent assay</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype)</td>
<td>ELISA assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Hypoxia Inducible Factor (HIF)  (nonspecified subtype)</td>
<td>Chemiluminescent assay</td>
<td>PC3 human prostate adenocarcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Fatty Acid Synthase inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Fatty Acid Synthase</td>
<td>Acetyl-CoA incorporation assay</td>
<td>SKBr3 human breast adenocarcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Cinanserin hydrochloride</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>Serotonin Receptor Antagonists;Signal Transduction Modulators</td>
<td>3C-Like Protease (viral)</td>
<td></td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Tomentin E</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Apoptosis Regulator Bcl-2 induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Apoptosis Regulator Bcl-2</td>
<td>Chemiluminescent assay</td>
<td>H9c2 rat cardiac myoblasts (hypoxic/reoxygenated)</td>
<td>MEC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Caspase-3 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Caspase-3</td>
<td>Acetyl-Asp-Glu-Val-Asp-p-nitroanilide as substrate</td>
<td>H9c2 rat cardiac myoblasts</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Apoptosis Regulator BAX inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Apoptosis Regulator BAX</td>
<td>Chemiluminescent assay</td>
<td>H9c2 rat cardiac myoblasts</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Transcriptional Repressor Protein YY1 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Transcriptional Repressor Protein YY1</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB453 human breast carcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Membrane-Associated Tyrosine- and Threonine-Specific cdc2-Inhibitory Kinase induction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Membrane-Associated Tyrosine- and Threonine-Specific cdc2-Inhibitory Kinase</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>SP Transcritption Factors inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>SP Transcritption Factors</td>
<td>Luciferine/luciferase assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Transcription Factor Sp1 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Transcription Factor Sp1</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Transcription Factor Sp3 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Transcription Factor Sp3</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Transcription Factor Sp4 inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Transcription Factor Sp4</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Wee1-Like Protein Kinase 1 (Wee1) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Wee1-Like Protein Kinase 1 (Wee1)</td>
<td>RNA assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Cancer, liver (hepatocellular carcinoma) remission/reduction, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Cancer, liver (hepatocellular carcinoma)</td>
<td>Colony formation assay</td>
<td>Hep3B human hepatocellular carcinoma cells</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>SKBr3 human breast adenocarcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>Chemiluminescent assay</td>
<td>H9c2 rat cardiac myoblasts</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>TBARS formation assay</td>
<td>H9c2 rat cardiac myoblasts</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>Hydroxylamine as substrate</td>
<td>H9c2 rat cardiac myoblasts (hypoxic/reoxygenated)</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>Spectrophotometric assay</td>
<td>H9c2 rat cardiac myoblasts (hypoxic/reoxygenated)</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Oxidative stress remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Oxidative stress</td>
<td>Spectrophotometric assay</td>
<td>H9c2 rat cardiac myoblasts</td>
<td>MIC</td>
<td>&lt;=</td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (in situ ductal carcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (in situ ductal carcinoma)</td>
<td>Cell counting assay</td>
<td>BT474 human breast ductal carcinoma cells (HER2 [ERBB2]-overexpressing)</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Flow cytometry assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MEC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Cell counting assay</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MCC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT)</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MCC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (MTT) @ 24 h</td>
<td>MDAMB231 human breast adenocarcinoma cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Transwell chamber assay</td>
<td>H1299 human non-small-cell lung cancer cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Wound closure assay</td>
<td>H1299 human non-small-cell lung cancer cells</td>
<td>MIC</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Glioblastoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Glioblastoma</td>
<td>Dye assay (MTT)</td>
<td>U87MG human glioblastoma cells</td>
<td>CC-50</td>
<td></td>
<td>5.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, esophagus remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, esophagus</td>
<td>Cell viability assay</td>
<td>YES2 human esophagus cancer cells</td>
<td>IC-50</td>
<td></td>
<td>5.09E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Malaria remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Signal Transduction Modulators;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Malaria</td>
<td>Flow cytometry assay</td>
<td>Erythrocytes, human</td>
<td>IC-50</td>
<td></td>
<td>5.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>beta-Galactosidase assay</td>
<td>HeLa human cervix adenocarcinoma cells (CD4+/CCR5+) transfected with HIV-1 LTRbeta-gal-positive</td>
<td>IC-50</td>
<td></td>
<td>5.32E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Infection, HIV remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Infection, HIV</td>
<td>beta-Galactosidase assay</td>
<td>HeLa human cervix adenocarcinoma cells (CD4+/CCR5+) transfected with HIV-1 LTRbeta-gal-positive</td>
<td>IC-50</td>
<td></td>
<td>5.32E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Proteasome Subunit beta Type-5 (PSMB5) inhibition, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Proteasome Subunit beta Type-5 (PSMB5)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>SSYA-10-001</td>
<td>NTPase inhibition, IN VITRO</td>
<td></td>
<td>NTPase</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Curcumin</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;CCND1 Expression Inhibitors;Glucose-6-Phosphatase Inhibitors;P-Glycoprotein (MDR-1; ABCB1) Inhibitors;HIV Integrase Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Signal Transduction Modulators;Antiinflammatory Drugs;Histone N-Acetyltransferase (HAT) Inhibitors;Microtubule-Associated Protein Tau (PHF-tau; MAPT) Aggregation Inhibitors;AP-1 Transcription Factor Complex Inhibitors;DNA Methyltransferase 1 (DNMT1) Inhibitors;Apoptosis Inducers;Prostaglandin G/H Synthase 1 (PTGS1; COX-1) Inhibitors;Antioxidants;Angiogenesis Inhibitors;EGFR Expression Inhibitors;Cell Division Protein FtsZ (Bacterial) Inhibitors;Free Radical Scavengers;Lipoxygenase Inhibitors;Wnt Signaling Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>5.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>RH-01</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td></td>
<td>Coronavirus</td>
<td>IC-50</td>
<td></td>
<td>5.72E-06</td>
<td>M</td>
</tr>
<tr>
<td>(-)-Savinin</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Drugs Acting on Tumor Necrosis Factor (TNF) Receptors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>A549 human non-small-cell lung carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>5.75E-06</td>
<td>M</td>
</tr>
<tr>
<td>Ferruginol</td>
<td>Leishmaniasis remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Lipid Peroxidation Inhibitors;Antioxidants;Apoptosis Inducers</td>
<td>Leishmaniasis</td>
<td>Amastigote assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>5.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Loperamide hydrochloride</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;mu-Opioid Receptor Agonists;Atrial Natriuretic Peptide B (NPR2; Guanylate Cyclase B) Receptor Antagonists</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Dye assay (MTS)</td>
<td>VeroE6 African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>5.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Loperamide hydrochloride</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;mu-Opioid Receptor Agonists;Atrial Natriuretic Peptide B (NPR2; Guanylate Cyclase B) Receptor Antagonists</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Viral replication assay</td>
<td></td>
<td>IC-50</td>
<td></td>
<td>5.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Papyriflavonol A</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;Phospholipase A2 (PLA2) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Uncompetitive inhibition mode</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>5.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>SG-85</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>3C-Like Protease (NL63 Coronavirus) (HCoV-NL63) Inhibitors;3C Protease (Enterovirus 71) Inhibitors;3C-Like Protease (EMC Coronavirus) (HCoV-EMC) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td></td>
<td>Coronavirus</td>
<td>IC-50</td>
<td></td>
<td>6.06E-06</td>
<td>M</td>
</tr>
<tr>
<td>SR9EK3</td>
<td>Nephrotoxicity induction, IN VITRO</td>
<td></td>
<td>Nephrotoxicity</td>
<td>Dye assay</td>
<td>Vero African green monkey kidney cells</td>
<td>CC-50</td>
<td></td>
<td>6.15E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Melanoma, metastatic remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Melanoma, metastatic</td>
<td>Dye assay (alamar blue)</td>
<td>B16F10 mouse metastatic melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.30E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SW480 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SW480 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SW480 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.40E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SW480 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.48E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, colon (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, colon (adenocarcinoma)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>SW480 human colon adenocarcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.48E-06</td>
<td>M</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td></td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td></td>
<td>Vero African green monkey kidney cells</td>
<td>IC-50</td>
<td></td>
<td>6.50E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Dye assay</td>
<td>A549 human non-small-cell lung carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.65E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>6.70E-06</td>
<td>M</td>
</tr>
<tr>
<td>Psoralidin</td>
<td>Estrogen Receptor beta (ERbeta) agonism, IN VITRO</td>
<td>Estrogen Receptor (ER) beta Agonists;Prostaglandin G/H Synthase 2 (PTGS2; COX-2) Inhibitors;Estrogen Receptor (ER) alpha Agonists;5-Lipoxygenase Inhibitors;Signal Transduction Modulators;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;NF-kappaB (NFKB) Activation Inhibitors;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Caspase Activators;Apoptosis Inducers</td>
<td>Estrogen Receptor beta (ERbeta)</td>
<td>Luciferine/luciferase assay</td>
<td>CV1 African green monkey kidney fibroblasts transfected with ERbeta receptor</td>
<td>EC-50</td>
<td></td>
<td>6.88E-06</td>
<td>M</td>
</tr>
<tr>
<td>Quercetin</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Catechol-O-Methyl Transferase (COMT) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Signal Transduction Modulators;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Xanthine Oxidase Inhibitors;EGFR (HER1; erbB1) Inhibitors;Cytokine Production Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Aldose Reductase Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Free Radical Scavengers;Epigenetic Modifier Modulators;Wnt Signaling Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Uncompetitive inhibition mode</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>7.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Melanoma</td>
<td>Dye assay (MTS)</td>
<td>SKMEL2 human melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, stomach remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, stomach</td>
<td></td>
<td>N87 human gastric carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Mucroporin-M1</td>
<td>Severe acute respiratory syndrome (SARS-CoV) remission/reduction, IN VITRO</td>
<td>Cell Membrane Disrupting Agents</td>
<td>Severe acute respiratory syndrome (SARS-CoV)</td>
<td>Plaque assay</td>
<td>HeLa human cervix adenocarcinoma cells</td>
<td>IC-50</td>
<td></td>
<td>7.12E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.26E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, thyroid, anaplastic remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, thyroid, anaplastic</td>
<td>Dye assay (sulforhodamine B)</td>
<td>8505C human anaplastic thyroid carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.26E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Arg-Leu-Arg-Gly-Gly-7-amino-4-methylcoumarin as substrate</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>7.30E-06</td>
<td>M</td>
</tr>
<tr>
<td>Papyriflavonol A</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;Phospholipase A2 (PLA2) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>7.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, lung (non-small cell) (NSCLC) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, lung (non-small cell) (NSCLC)</td>
<td>Dye assay (sulforhodamine B)</td>
<td>A549 human non-small-cell lung carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.60E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Cancer, breast (in situ ductal carcinoma) remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Cancer, breast (in situ ductal carcinoma)</td>
<td>Clonogenic assay</td>
<td>T47D human breast ductal carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.66E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Hepatoblastoma remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Hepatoblastoma</td>
<td>Dye assay (alamar blue)</td>
<td>HepG2 human hepatoblastoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.80E-06</td>
<td>M</td>
</tr>
<tr>
<td>Pristimerine</td>
<td>Cancer, breast (adenocarcinoma) remission/reduction, IN VITRO</td>
<td>3C-Like Protease (SARS-CoV) Inhibitors;Apoptosis Inducers;Microtubule Destabilizers (Tubulin Polymerization Inhibitors);Antimitotic Drugs</td>
<td>Cancer, breast (adenocarcinoma)</td>
<td>Dye assay (alamar blue)</td>
<td>MCF7 human breast adenocarcinoma cells (hormone-dependent)</td>
<td>CC-50</td>
<td></td>
<td>7.90E-06</td>
<td>M</td>
</tr>
<tr>
<td>Isobavachalcone</td>
<td>Cancer, ovary remission/reduction, IN VITRO</td>
<td>Inducible Nitric Oxide Synthase (NOS-2) Inhibitors;Steroid 5alpha-Reductase Inhibitors;Drugs Targeting Beta-Amyloid;Signal Transduction Modulators;Autophagy Inducers;Papain-Like Protease (PLpro) (SARS-CoV) Inhibitors;Antioxidants</td>
<td>Cancer, ovary</td>
<td>Dye assay (MTT)</td>
<td>OVCAR8 human ovary carcinoma cells</td>
<td>CC-50</td>
<td></td>
<td>7.92E-06</td>
<td>M</td>
</tr>
<tr>
<td>Broussochalcone A</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS) inhibition, IN VITRO</td>
<td>Signal Transduction Modulators;Protein Kinase C (PKC) Inhibitors</td>
<td>Replicase Polyprotein 1ab (pp1ab) (SARS)</td>
<td>Uncompetitive inhibition mode</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>8.00E-06</td>
<td>M</td>
</tr>
<tr>
<td>Quercetin</td>
<td>NTPase inhibition, IN VITRO</td>
<td>Catechol-O-Methyl Transferase (COMT) Inhibitors;Drugs Targeting on Quorum Sensing Signaling;Tyrosine-Protein Phosphatase Non-Receptor Type 1 (PTPN1; PTP-1B) Inhibitors;MAO-A Inhibitors;NAD-Dependent Protein Deacetylase Sirtuin-1 (SIRT1) Activators;Signal Transduction Modulators;Lysosomal alpha-Glucosidase (GAA) Inhibitors;Xanthine Oxidase Inhibitors;EGFR (HER1; erbB1) Inhibitors;Cytokine Production Inhibitors;Antioxidants;Steryl-Sulfatase (STS) Inhibitors;Aldose Reductase Inhibitors;Sodium Channel Protein Type 5 Subunit alpha (Nav1.5) Channel Blockers;Free Radical Scavengers;Epigenetic Modifier Modulators;Wnt Signaling Inhibitors</td>
<td>NTPase</td>
<td>Fluorescent assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>IC-50</td>
<td></td>
<td>8.10E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Melanoma</td>
<td>Dye assay (sulforhodamine B)</td>
<td>518A2 human melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>8.13E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulinic acid</td>
<td>Melanoma remission/reduction, IN VITRO</td>
<td>Signal Transduction Modulators;3C-Like Protease (SARS-CoV) Inhibitors;Caspase 3 Activators;Caspase 8 Activators;NF-kappaB (NFKB) Activators;Apoptosis Inducers;DNA Topoisomerase I Inhibitors;Diacylglycerol Acyltransferase (DGAT) Inhibitors</td>
<td>Melanoma</td>
<td>Dye assay (sulforhodamine B)</td>
<td>518A2 human melanoma cells</td>
<td>CC-50</td>
<td></td>
<td>8.13E-06</td>
<td>M</td>
</tr>
<tr>
<td>Betulonic acid</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>E3 Ubiquitin-Protein Ligase SIAH2 Inhibitors;Lysosomal alpha-Glucosidase (GAA) Inhibitors</td>
<td>3C-Like Protease (viral)</td>
<td>Spectrophotometric assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>8.20E-06</td>
<td>M</td>
</tr>
<tr>
<td>Eckol</td>
<td>3C-Like Protease (viral) inhibition, IN VITRO</td>
<td>Lipid Peroxidation Inhibitors;Tyrosinase Inhibitors;Free Radical Scavengers</td>
<td>3C-Like Protease (viral)</td>
<td>Fluorescence resonance energy transfer (FRET) assay</td>
<td>Coronavirus (SARS-associated)</td>
<td>Ki</td>
<td></td>
<td>8.20E-06</td>
<td>M</td>
</tr>
</tbody>
</table>
</details>

<h3 id="unannotated-preclinical-studies">Unannotated preclinical studies</h3>
<ul>
<li>
<p>A collection of 816 records for 479 molecules from various sources. We currently don't have the capability to annotate the sources or confirm the correctness of all datasets. This dataset may contains missing values and "dirty" data. Please use the data carefully and make your own effort to confirm the data source (journals, patents, websites) and extract useful (signal) information from the set. Some datasets use standardlized value PX=-log[M].   </p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/AllAssay_coronavirus_all.csv">Full dataset</a></p>
</li>
<li>
<p>Some subsets extracted:</p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/AllAssay_coronavirus_active.csv"><em>PX&gt;6(measurement &lt;1uM) active set</em></a></p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/coronavirus_IC50_for_562_molecules.csv"><em>IC50 values for 562 molecules</em></a></p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/coronavirus_Ki_inhibition_constant_for_207_molecules.csv"><em>Ki inhibition constant for 207 molecules</em></a></p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/coronavirus_inhibition_rate_for_153_molecules.csv"><em>Inhibition rate for 153 molecules</em></a></p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/coronavirus_EC50_for_30_molecules.csv"><em>EC50 values for 30 molecules</em></a></p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/coronavirus_pKi_for_14_molecules.csv"><em>pKi values for 14 molecules</em></a></p>
</li>
<li>
<p>SMILES of 986 molecules tested for coronavirus, but we are not sure if they are active or inactive</p>
</li>
<li><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/AllAssay_coronavirus_986_SMILES.csv">SMILES</a></li>
</ul>
<h3 id="literature-mining">Literature Mining</h3>
<ul>
<li>A comprehensive literature mining result kindly provided by <a href="https://www.causaly.com">Causaly</a>, focusing on chemicals/drugs, genes and molecular mechanisms. This data includes 2090 relationships, 1229 aggregrate relationships, and 976 articles based on a search query of "Chemicals&amp;Drugs,Genes,Cellular&amp;Molecular Mechanisms [AFFECTING] [Genus:Coronavirus]" with the data source coming from MEDLINE and PubMedCentral. This search resulted in several Target Concepts including: sars coronavirus, middle east respiratory syndrome coronavirus, human coronavirus, etc.</li>
<li><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/Causaly-GHDDI_dataset.xlsx">Full dataset</a></li>
</ul>
<p>The following figure is the keyword relationship network: </p>
<p><img alt="Image of network" src="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/graph_resized.png" /></p>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/graph_network_causaly.png">Full Image</a></p>
<ul>
<li>
<p>The aggregate relationship data can be found in this <a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/literature_aggregate_relationships.xlsx">dataset</a></p>
</li>
<li>
<p>This data describes source concept items and classifies them into different categories. Some relevant categories include: Amino Acid Peptide Protein, Biologically Active Substance, Chemical, Nucleic Acid, etc.</p>
</li>
<li>
<p>Literature articles and relationships data gives a list of 977 relevant articles and shows the evidence of the relationship from the original article.</p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/literature_articles_and_relationships.xlsx">Dataset</a></p>
</li>
<li>
<p>Literature evidence data lists all relevant source concepts (biological substances, chemicals, etc) and its relation to an article. Overall, there are over 2000 relevant pieces of information relevant to coronavirus. </p>
</li>
<li>
<p><a href="https://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/literature_articles_all.xlsx">Dataset</a></p>
</li>
</ul>
<p><details>
      <summary>A few selected records</summary></p>
<table>
<thead>
<tr>
<th>Source Concept</th>
<th>Source Concept Categories</th>
<th>Relationship Type</th>
<th>Target Concept</th>
<th>Count of Evidence</th>
<th>Evidence contains clinical studies?</th>
<th>Count of Evidence per rel type</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclosporine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>11</td>
<td>no</td>
<td>DOWNREGULATE: 11</td>
</tr>
<tr>
<td>"rna, small interfering"</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>9</td>
<td>no</td>
<td>DOWNREGULATE: 9</td>
</tr>
<tr>
<td>linoleic acid</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UPREGULATE: 1"</td>
</tr>
<tr>
<td>resveratrol</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>7</td>
<td>no</td>
<td>"DOWNREGULATE: 6, UPREGULATE: 1"</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>14</td>
<td>no</td>
<td>"DOWNREGULATE: 12, UPREGULATE: 2"</td>
</tr>
<tr>
<td>human leukocyte interferon</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>17</td>
<td>no</td>
<td>"DOWNREGULATE: 11, UNIDIRECTIONAL: 4, UPREGULATE: 1, NEG_UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>gs-5734</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>4</td>
<td>no</td>
<td>DOWNREGULATE: 4</td>
</tr>
<tr>
<td>zinc</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>4</td>
<td>no</td>
<td>DOWNREGULATE: 4</td>
</tr>
<tr>
<td>linoleic acid</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>2</td>
<td>no</td>
<td>"UPREGULATE: 1, DOWNREGULATE: 1"</td>
</tr>
<tr>
<td>fk-506</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus nl63</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>human leukocyte interferon</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>8</td>
<td>no</td>
<td>"DOWNREGULATE: 5, UNIDIRECTIONAL: 2, UPREGULATE: 1"</td>
</tr>
<tr>
<td>lopinavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>4</td>
<td>no</td>
<td>DOWNREGULATE: 4</td>
</tr>
<tr>
<td>ribavirin</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>6</td>
<td>no</td>
<td>"DOWNREGULATE: 5, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>gs-5734</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>recombinant interferon alfa</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>5</td>
<td>no</td>
<td>"DOWNREGULATE: 4, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>"5-(n,n-hexamethylene)amiloride"</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>4</td>
<td>no</td>
<td>DOWNREGULATE: 4</td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>interferon type i</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>5</td>
<td>no</td>
<td>"DOWNREGULATE: 3, UNIDIRECTIONAL: 1, UPREGULATE: 1"</td>
</tr>
<tr>
<td>monoclonal antibodies</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>6</td>
<td>no</td>
<td>"DOWNREGULATE: 3, UNIDIRECTIONAL: 2, UPREGULATE: 1"</td>
</tr>
<tr>
<td>glycyrrhizic acid</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>kinase inhibitor [epc]</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>3</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>emodin</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>emodin</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>"coronavirus oc43, human"</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>beta-thujaplicin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>ubiquitin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>DOWNREGULATE: 3</td>
</tr>
<tr>
<td>nucleoside analogs</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>3</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>proteasome inhibitor</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>mycophenolic acid</td>
<td>Antibiotic</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>loperamide</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>cyclophilins</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>"DOWNREGULATE: 1, UPREGULATE: 1"</td>
</tr>
<tr>
<td>cytokine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>3</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>lopinavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>cyclosporine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>alisporivir</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>glycosyltransferase</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>methyltransferase</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>u 18666a</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>"5-(n,n-hexamethylene)amiloride"</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>niclosamide</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>"dpp4 protein, human"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>5</td>
<td>no</td>
<td>"DOWNREGULATE: 3, UPREGULATE: 1, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>glycoproteins</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>"DOWNREGULATE: 1, UPREGULATE: 1"</td>
</tr>
<tr>
<td>fumaric acid</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>adenoviral vector</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>tapi-2</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>monoclonal antibodies</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>porcine respiratory coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>s antibody</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>bovine coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>interferon-alpha2b</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UNIDIRECTIONAL: 1"</td>
</tr>
<tr>
<td>human immunodeficiency virus 1 fusion inhibitor [epc]</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>ribavirin</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>12</td>
<td>no</td>
<td>"DOWNREGULATE: 5, NEG_DOWNREGULATE: 4, UNIDIRECTIONAL: 2, UPREGULATE: 1"</td>
</tr>
<tr>
<td>platelets product</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>tylophorine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>"UPREGULATE: 1, DOWNREGULATE: 1"</td>
</tr>
<tr>
<td>riboflavin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>recombinant interferon beta</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"antibodies, neutralizing"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>5</td>
<td>no</td>
<td>"DOWNREGULATE: 2, UPREGULATE: 1, NEG_UPREGULATE: 1, NEG_DOWNREGULATE: 1"</td>
</tr>
<tr>
<td>ribavirin</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>immune sera</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>2</td>
<td>no</td>
<td>DOWNREGULATE: 2</td>
</tr>
<tr>
<td>nim-811</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus nl63</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>alisporivir</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus nl63</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>fk-506</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>fk-506</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>s-nitroso-n-acetylpenicillamine</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>hiv protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nelfinavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>phospholipase c</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>disulfiram</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>disulfiram</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>scorpion venoms</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>interferon gamma [epc]</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>acetylglucosamine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>"coronavirus oc43, human"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>gs-5734</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>terconazole</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>terconazole</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>phenanthrenes</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>pyrithione</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>"coronavirus oc43, human"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>saikosaponin b2</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>isobavachalcone</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>herbacetin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>helichrysetin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>isoquercitrin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>fc receptor</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>alisporivir</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>decanoylrvkrchloromethylketone</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>gs-5734</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nucleoside analogs</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nucleoside analogs</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nucleoside analogs</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cardiotonic agents</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>sodium</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>aminoquinoline antimalarial (product)</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>interleukins</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>thiothixene</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>clomipramine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>thioxanthenes</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>clomipramine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>thiothixene</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>thioxanthenes</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>adenosine deaminase</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>chloroquine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>tetra(4-n-methylpyridyl)porphine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>alisporivir</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>teicoplanin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>dalbavancin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>telavancin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>oritavancin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"antibodies, monoclonal, humanized"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ssya10-001</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>mercaptopurine</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>thioguanine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ssya10-001</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>pj-34</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>sb 203580</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>interferon-alpha2b</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>synthetic peptide</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>chinese herbs</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nitric oxide</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>amiloride</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>amiodarone</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cystatins</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>glycine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>anthelmintics</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>anthelmintics</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>interferon beta-1a</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>polypeptide c</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>hexachlorophene</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>bovine coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>hexachlorophene</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human enteric coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>hexachlorophene</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>palmitic acid</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>mouse monoclonal antibody</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>gemcitabine</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>sotrastaurin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protein kinase c inhibitor</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>toremifene citrate</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>bcx4430</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"ifitm1 protein, human"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>glucose</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>antiviral agents</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>iota-carrageenan</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>"coronavirus oc43, human"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>tylonycteris bat coronavirus hku4</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>omacetaxine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>bovine coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>omacetaxine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>human enteric coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>omacetaxine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>dna helicases</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cysteine proteases</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>e 64</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>camostate-mesilate</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>camostate-mesilate</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>e 64</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>kinase inhibitor [epc]</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protease inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>bacillus intermedius ribonuclease</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>bacillus intermedius ribonuclease</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nafamostat</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ritonavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"m protein, multiple myeloma"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>porcine respiratory coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>u 18666a</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>human leukocyte interferon</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>glycyrrhizic acid</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>nitazoxanide</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>m nos antibody</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>antiviral agents</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>camostat</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>baicalin</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>baicalein</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>zinc</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>enzyme inhibitor drugs</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>human coronavirus hku1</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>paired basic amino acid cleaving enzyme</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus hku1</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>short hairpin rna</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>eosinophil cationic protein</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>mizoribine</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>aziridine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ritonavir</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>recombinant interferon beta-1a</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>veratridine</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>dactinomycin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>stallimycin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>recombinant interferon alfa</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cytokine</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protein domain</td>
<td>Amino Acid Sequence</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>immunoglobulin domains</td>
<td>Amino Acid Sequence</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>heparitin sulfate</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>betacoronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>itraconazole</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>recombinant interferon beta</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>cysteine proteases</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>papillomavirus transforming protein e6</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>memantine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>"coronavirus oc43, human"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>heparin</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ethanol</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>structural protein</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, feline"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>structural protein</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, canine"</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>leupeptin</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>protein antibody</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>azauridine</td>
<td>"Nucleic Acid, Nucleoside, or Nucleotide"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>guanidine hydrochloride</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>resveratrol</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus rna</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"antibodies, anti-idiotypic"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>phenothiazine</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>recombinant interleukin-4</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>recombinant rantes</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>"tnf protein, human"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>human coronavirus 229e</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>polyanion</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>ads j1</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>prostaglandin-endoperoxide synthase</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>plant extracts</td>
<td>Biologically Active Substance</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>hla complex</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>DOWNREGULATE: 1</td>
</tr>
<tr>
<td>macrolides</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus rna</td>
<td>2</td>
<td>no</td>
<td>"NEG_UPREGULATE: 1, NEG_DOWNREGULATE: 1"</td>
</tr>
<tr>
<td>"antibodies, anti-idiotypic"</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>4</td>
<td>no</td>
<td>"DOWNREGULATE: 2, NEG_UPREGULATE: 2"</td>
</tr>
<tr>
<td>ssaa09e3</td>
<td>Organic Chemical</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>1</td>
<td>no</td>
<td>NEG_DOWNREGULATE: 1</td>
</tr>
<tr>
<td>caspase</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>"coronavirus, canine"</td>
<td>1</td>
<td>no</td>
<td>NEG_DOWNREGULATE: 1</td>
</tr>
<tr>
<td>phospholipase d</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>genus: coronavirus</td>
<td>1</td>
<td>no</td>
<td>NEG_DOWNREGULATE: 1</td>
</tr>
<tr>
<td>proteolytic enzyme</td>
<td>"Amino Acid, Peptide, or Protein"</td>
<td>DOWNREGULATE</td>
<td>sars coronavirus</td>
<td>2</td>
<td>no</td>
<td>"UPREGULATE: 1, NEG_DOWNREGULATE: 1"</td>
</tr>
<tr>
<td>dipeptidyl-peptidase iv inhibitors</td>
<td>Pharmacologic Substance</td>
<td>DOWNREGULATE</td>
<td>middle east respiratory syndrome coronavirus</td>
<td>3</td>
<td>no</td>
<td>"NEG_DOWNREGULATE: 2, NEG_UNIDIRECTIONAL: 1"</td>
</tr>
</tbody>
</table>
</details>

<p><br>
<br></p>
<p>Your <a href="https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues"><strong>feedback</strong></a> is highly appreciated.</p>
              
            </div>
          </div>
          <footer>
  
    <div class="rst-footer-buttons" role="navigation" aria-label="footer navigation">
      
        <a href="../nCov_Targets/" class="btn btn-neutral float-right" title="Target Validation">Next <span class="icon icon-circle-arrow-right"></span></a>
      
      
        <a href="../drug_candidates/" class="btn btn-neutral" title="2019-nCoV Community Effort"><span class="icon icon-circle-arrow-left"></span> Previous</a>
      
    </div>
  

  <hr/>

  <div role="contentinfo">
    <!-- Copyright etc -->
    
  </div>

  Built with <a href="http://www.mkdocs.org">MkDocs</a> using a <a href="https://github.com/snide/sphinx_rtd_theme">theme</a> provided by <a href="https://readthedocs.org">Read the Docs</a>.
</footer>
      
        </div>
      </div>

    </section>

  </div>

  <div class="rst-versions" role="note" style="cursor: pointer">
    <span class="rst-current-version" data-toggle="rst-current-version">
      
      
        <span><a href="../drug_candidates/" style="color: #fcfcfc;">&laquo; Previous</a></span>
      
      
        <span style="margin-left: 15px"><a href="../nCov_Targets/" style="color: #fcfcfc">Next &raquo;</a></span>
      
    </span>
</div>
    <script>var base_url = '..';</script>
    <script src="../js/theme.js" defer></script>
      <script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML" defer></script>
      <script src="../search/main.js" defer></script>

</body>
</html>
